I thought this was interesting.
It shows a change in emphasis in NIH funding allocations to AD research between 2008 and 2017.
It shows less emphasis on β-amyloid and more on "Other", genetics, vascular and bioenergetic work.
Given the complexity of AD this looks sensible to me.
The Alzheimer’s gamble: NIH tries to turn billions in new funding into treatment for deadly brain disease | Science | AAAS